Modulators of the integrated stress response pathway

ES3074050T3Undetermined Publication Date: 2026-07-16
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
ES · ES
Patent Type
Patents
Filing Date
2021-03-10
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

There is a need for new compounds that can effectively modulate the integrated stress response pathway with improved pharmacokinetic properties for the treatment of related diseases such as cancer and neurodegenerative disorders.

Method used

Development of a new class of 1,3-dioxane derivatives as modulators of the integrated stress response pathway, characterized by specific substituents and functional groups that enhance activity, solubility, selectivity, and reduce side effects.

Benefits of technology

These compounds effectively modulate the integrated stress response pathway, offering potential therapeutic benefits for diseases like cancer and neurodegenerative disorders by stabilizing eIF2B and reducing phosphorylated eIF2alpha levels, thereby improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers, or stereoisomers thereof, where R1, R2, R2a, R3, Ra1, Ra2, Ra3, Ra4, Ra5, Ra6, A1, and A2 have the meanings indicated in the description and claims. The invention also relates to pharmaceutical compositions comprising such compounds, their use as a medicament, and in a method for the treatment and prevention of one or more diseases or disorders associated with the integrated stress response.
Need to check novelty before this filing date? Find Prior Art